Nitric oxide differentially affects ERK and Akt in type 1 and type 2 diabetic rats

Area of Science:

• Vascular biology
• Diabetology
• Pharmacology

Background:

• Nitric oxide (NO) effectively inhibits neointimal hyperplasia in type 2 diabetic rats but not in type 1 diabetic rats.
• Insulin signaling involves ERK and Akt pathways, suggesting NO's differential effects in diabetes types.
• Hypothesis: NO differentially impacts ERK and Akt activity in type 1 vs. type 2 diabetic models.

Purpose of the Study:

• To investigate the differential effects of nitric oxide (NO) on ERK and Akt pathways in type 1 and type 2 diabetic rat models.
• To explore the relationship between NO, insulin signaling pathways, and neointimal hyperplasia inhibition.
• To identify potential biomarkers for predicting NO efficacy in diabetic vascular disease.

Main Methods:

• Type 2 diabetes induced in Zucker diabetic fatty (ZDF) rats; type 1 diabetes induced in Sprague-Dawley rats using streptozotocin (STZ).
• Carotid artery injury model established in both diabetic models.
• Animals treated with PROLI/NO (20 mg/kg) or vehicle post-injury; pERK and pAkt levels assessed.

Main Results:

• NO reduced pERK and pAkt levels in non-diabetic and type 1 diabetic rats (STZ), but increased pAkt in type 2 diabetic rats (ZDF).
• NO increased total pERK and pAkt in ZDF rats, while decreasing pAkt in non-diabetic and STZ rats at 14 days.
• The pERK:pAkt ratio increased with NO in non-diabetic and STZ rats, but decreased in ZDF rats.

Conclusions:

• Nitric oxide (NO) exhibits differential effects on ERK and Akt expression in type 1 versus type 2 diabetic rats.
• The pERK:pAkt ratio serves as a potential surrogate marker to predict the efficacy of NO in inhibiting neointimal hyperplasia.
• Findings highlight distinct molecular mechanisms underlying NO's action in different diabetic contexts.